| USA, asthmatic children (Gilliland, 2002)66
|
Case–control |
Asthma
Wheezing |
GSTM1: null(−) (1p13,3) |
ETS
In utero ETS |
2950 |
In utero exposure +GSTM1(−):
Early onset asthma OR = 1.6 (1.0–2.5)
Current asthma OR = 1.7(1.1–2.8)
Persistent asthma OR = 1.6(1.1–2.4) |
| Germany, asthmatic children (Kabesch, 2004)67
|
Case–control |
Asthma
Allergic traits |
GSTM1: null(−) (1p13,3)
GSTT1: null(−) (22q11,2) |
ETS
In utero ETS |
3054 |
In utero exposure:
GSTM1(−): OR = 5.5 (1.6–18.6) asthma and symptoms
GSTT1: OR increased only for wheeze ever and current cough |
| USA, 144 families (Colilla, 2003)28
|
Family based case–control |
Asthma |
LD study |
ETS during infancy |
144 families |
Z for case‐exposed
1p 97cM Z = 1.29[p = 0.034] D1S1669.D1S1665
5q 240cM Z = 1.23[p = 0.051] D5S1505.D5S816
17p 3cM Z = 1.12[p = 0.016] D17S1308 |
| Netherland, 200 families (Meyers, 2005)69
|
Family based case–control |
Asthma
BHR |
LD study |
ETS during infancy |
268/272 |
Exposed v non‐exposed LOD
BHR
3p:2.17 v 1.12 (p>0.05. M test)
Asthma
5q:2.54 v 0.15
3p:2.63 v 0.71 |
| Mexico and P.Rico, Latin asthmatics (Choudhry, 2005)68
|
Family based case–control |
Asthma and severity
IgE levels |
CD14: SNPs −159, −810, +1437
(5q31) |
ETS during infancy |
Mex: 120/174
PR: 149/216 |
+1437 GG/GC: lower FEV1 among subjects with ETS p = 0.002
SNP −159 associated with levels of IgE p = 0.005 |
| China, general population (Wang, 2001)73
|
Case–control |
Asthma |
ADRB2: Gly16Arg, Gln27Glu
(5q31–33) |
Cigarette smoking |
128/136 |
Arg/Arg16: OR = 7.81 (2.07–29.5)
Arg/Arg16 dose‐response relationship
Dose‐response relationship |
| USA, smokers
(Joos, 2003)74
|
Case–control |
Decline FEV1
Bronchodilatory response (BDR)
Non‐specific BHR (NSBH) |
ADRB2: Gly16Arg;Gln27Glu
(5q31–33) |
Cigarette smoking |
Decline FEV1
Fast: 282
No: 305 |
Significant differences in genotype distribution between the two groups of decline
Glu/Gln27 genotype OR = 0.56 (0.40–0.78. p = 0.0018) decline lung function |
